TherapyX has developed a proprietary technology known as EXStaM, which is a novel process for producing sustained-release microparticulate protein therapeutics. This technology allows for the effective encapsulation of biological macromolecules while maintaining their full biological activity. The EXStaM platform is designed to deliver these therapeutics via parenteral, oral, and mucosal routes, ensuring that the active proteins are released in a controlled manner within the disease microenvironment. This capability not only enhances therapeutic efficacy but also reduces systemic toxicity, making the products more effective and safer for patients.

In addition to its innovative drug delivery system, TherapyX is focused on developing a pipeline of products aimed at treating various conditions, including cancer and infectious diseases. The company has partnered with leading institutions and experts to advance its research, including collaborations for the development of immune therapies targeting pancreatic cancer and gonorrhea. TherapyX's commitment to intellectual property protection through aggressive patent filings further underscores its dedication to innovation in the pharmaceutical industry, positioning it as a key player in the development of next-generation therapeutics.

United States

TherapyX Inc. is changing the future of pharmaceuticals using revolutionary technology. They encapsulate large biological molecules in an orally ingestible form, allowing these molecules to remain fully intact.

TherapyX

Company Details